HonorStocks Biotech Gold Oil Mining China Asian MENU
Biotech Gold Oil Mining China Asian
Find Tomorrow's Winners Today

Stock technical analysis
Rating Flag Rating Flag Rating Flag Rating Flag Rating Flag
sell neutral buy
Novavax, Inc. (NVAX)
104.33  24.89  (31.33%) 07-07 15:52
Open: 104 High: 111.77
Pre.close: 79.44 Low: 95.5
Volume: 25,743,320 Ave vol: 9,434,966
52w High: 111.77 52w Low: 3.54
MA(50): 58.004 MA(200): 23.725
EPS: -3.833 P/E Ratio: 0
Company profile
Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.novavax.com
Market Cap (M): 6,123
Shares Out (M): 59
Novavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate that in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase III clinical trial for treating seasonal influenza in older adults. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, and the immune systems attack against microorganisms, as well as to allow immunization with much lower doses of antigen.
Technical analysis
Overall: Outperform
MA: Bullish MACD: Bullish
KDJ: Bullish RSI: Bullish
Target 1: 130.55 Target 2: 152.48
Resist 1: 111.77 Resist 2: 130.55
Support 1: 67.73 Support 2: 40.50
Company key metrics
Revenue per Share: 0.7744
Net Income per Share: -5.506
Cash per Share: 3.2707
Book Value per Share: -7.7185
Price to Sales: 9.0398
Price to Book Value: -0.9069
Earnings Yield: -0.7866
Dividend Yield: 0
Debt to Equity: -1.9298
Debt to Assets: 2.0755
Financial analysis
Price to Book Value: Underperform
Return on Assets: Neutral
Return on Equity: Outperform
Discounted cash flow: Outperform
Price to Earnings: Underperform
Debt to Equity: Underperform
Stock Charts
Headline news
Tue, 07 Jul 2020
NVAX Stock Price: Novavax Inc.surging 34% after $1.6 billion COVID-19 vaccine candidate grant - FXStreet

Mon, 06 Jul 2020
Novavax, Inc. (NVAX) future in Healthcare Sector - The News Heater

Tue, 07 Jul 2020
Novavax Covid Vaccine Gets $1.6 Billion in U.S. Funding - Bloomberg

Tue, 07 Jul 2020
Boiling and ready to burst as Novavax Inc. (NVAX) last month performance was 77.88% - The InvestChronicle

Tue, 30 Jun 2020
Analysts Just Published A Bright New Outlook For Novavax, Inc.'s (NASDAQ:NVAX) - Yahoo Finance

Fri, 19 Jun 2020
Novavax, Inc. (NVAX) Shares March Higher, Can It Continue? - Yahoo Finance

HonorStocks, Find Tomorrow's Winners Today

©HonorStocks.com | U.S. stock markets, stock quotes and stock analysis. Data and information is provided for informational purposes only, is not intended for trading purposes and is not investment advice. Neither HonorStocks.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Market data provided by: IEX and Financial Modeling Prep

Privacy Policy: Third parties, including Google, may be placing and reading cookies on your browsers, or other methods to collect information as a result of ad serving on this website. Google's use of advertising cookies enables it and its partners to serve ads to you based on your visit to this site and/or other sites on the Internet. You may opt out of personalized advertising by visiting Ads Settings. If you choose to use this website, you agree to the collection and use of information in relation to this policy. The information collected is used for providing and improving the ads Service. We will not use or share information with anyone, and we do not store any data from users.